《大行》花旗降荣昌生物(09995.HK)评级至“沽售/高风险”近期股价升幅反映过度乐观预期

阿斯达克财经
Jun 30, 2025

花旗发表报告指,荣昌生物(09995.HK) 向Vor Bio授出泰它西普大中华外独家开发权。据此,Vor Bio应向荣昌生物及荣普合伙支付总价值1.25亿美元的代价,其中包括公司将从Vor Bio取得4,500万美元的首付款和Vor Bio将向荣普合伙发行价值8,000万美元的认股权证,金额及合作力度均低于市场预期,投资者期望与全球大药厂合作预付额为数亿美元。报告指,泰它西普在AAN2025会议...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10